Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $128.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price raised by Royal Bank of Canada from $123.00 to $128.00 in a report released on Wednesday morning, Benzinga reports. They currently have a sector perform rating on the stock. A number of other equities analysts have also recently commented on the company. Raymond James boosted […]
More Stories
Difference Between “No Location Found” and “Location Not Available” on iPhone
There’s no doubt that location tracking is one of the most crucial features in today’s mobile devices. It helps the...
Top Grocery Stocks To Follow Now – June 25th
Uber Technologies, Berkshire Hathaway, and Costco Wholesale are the three Grocery stocks to watch today, according to MarketBeat’s stock screener...
International Assets Investment Management LLC Acquires 956 Shares of Schwab U.S. Large-Cap Growth ETF (NYSEARCA:SCHG)
International Assets Investment Management LLC grew its position in shares of Schwab U.S. Large-Cap Growth ETF (NYSEARCA:SCHG – Free Report)...
Top Fintech Stocks To Watch Today – June 25th
MercadoLibre, UP Fintech, Rocket Companies, WEX, Carlyle Group, Q2, and DeFi Development are the seven Fintech stocks to watch today,...
Global Assets Advisory LLC Buys Shares of 1,479 Cincinnati Financial Corporation (NASDAQ:CINF)
Global Assets Advisory LLC bought a new stake in Cincinnati Financial Corporation (NASDAQ:CINF – Free Report) during the 1st quarter,...
Mill Capital Management LLC Sells 729 Shares of Johnson & Johnson (NYSE:JNJ)
Mill Capital Management LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.6% in...